Twist Bioscience Stock News

Zacks Investment Research cut shares of Twist Bioscience (NASDAQ:TWST) from a hold rating to a sell rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery []

Twist Bioscience Co. (NASDAQ:TWST) Research analysts at SVB Leerink cut their Q1 2022 earnings estimates for Twist Bioscience in a research report issued to clients and investors on Monday, November 22nd. SVB Leerink analyst P. Souda now anticipates that the company will earn ($1.12) per share for the quarter, down from their previous estimate [] The post Twist Bioscience Co. (NASDAQ:TWST) Expected to Earn Q1 2022 Earnings of ($1.12) Per Share appeared first on ETF Daily News .

Twist Bioscience Co. (NASDAQ:TWST) – Research analysts at SVB Leerink cut their Q1 2022 earnings estimates for shares of Twist Bioscience in a note issued to investors on Monday, November 22nd. SVB Leerink analyst P. Souda now forecasts that the company will post earnings of ($1.12) per share for the quarter, down from their prior […]

Bank of America Corp DE lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 7.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 67,270 shares of the companys stock after purchasing an additional 4,678 shares during the period. Bank of America Corp DEs holdings in []

In the last trading session, 1.39 million shares of the Twist Bioscience Corporation (NASDAQ:TWST) were traded. Most recently the company’s share price was $96.69, and it changed around -$1.48 or -1.51% from the last close, which brings the market valuation of the company to $4.83B. TWST currently trades at a discount to its 52-week high … Twist Bioscience Corporation (NASDAQ: TWST) Stock Forecast: By 2021, Bulls Expect $130.00 Per Share Read More »

Twist Bioscience (NASDAQ:TWST) released its quarterly earnings results on Monday. The company reported ($0.84) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.80) by ($0.04), MarketWatch Earnings reports. The company had revenue of $37.95 million during the quarter, compared to analysts expectations of $36.26 million. Twist Bioscience had a negative return []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 19,983 shares of Twist Bioscience stock in a transaction on Monday, November 22nd. The stock was sold at an average price of $101.83, for a total transaction of $2,034,868.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. []

Twist Bioscience Corp

On Monday, Twist Bioscience Corp (NASDAQ:TWST) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets opened, missing the consensus analyst expectation on earnings per share. However, TWST marginally beat the Street revenue forecast after a double-digit Y/Y sales growth. Twist posted FQ4 [] The post Twist Bioscience stock prediction after plunging 8% on earnings miss appeared first on Invezz.

Twist Bioscience Corporation (NASDAQ: TWST ) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million , beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, biopharma businesses. The Company shipped products to approximately 2,900 customers in fiscal 2021, versus about 2,200 in fiscal 2020. The Company posted a wider net loss of Full story available on Benzinga.com

On Monday, Twist Bioscience Corp (NASDAQ:TWST) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili